公开(公告)号：US20250041277A1

公开(公告)日：2025-02-06

申请号：US18715085

申请日：2022-12-01

Applicant: PFIZER INC.

Inventor： Lars ANDERS ,  Jerry LI ,  Tun Tun LIN ,  Ping WEI ,  Jing YANG ,  Todd Lee VANARSDALE

IPC: A61K31/4155 ,  A61K31/4196 ,  A61K31/506 ,  A61K31/565 ,  A61P35/00

Abstract: This disclosure relates to combination therapies for use in treating cancer, comprising a CDK2 inhibitor of Formula (I) and a selective CDK4 inhibitor of Formula (II), each as further described herein, optionally in further combination with an additional anti-cancer agent.

公开(公告)号：US20240000783A1

公开(公告)日：2024-01-04

申请号：US18041245

申请日：2021-08-10

Applicant: Pfizer Inc. ,  Astellas Pharma Inc.

Inventor： Lars ANDERS ,  Kimberly Hyunjung KIM ,  Danan LI ,  Elizabeth Anne MCMILLAN ,  Robert Andrew ROLLINS ,  Brendan Ayers VEENEMAN

IPC: A61K31/506 ,  A61K31/4166 ,  A61K45/06 ,  A61P35/00

CPC classification number: A61K31/506 ,  A61K31/4166 ,  A61K45/06 ,  A61P35/00

Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) or a pharmaceutically acceptable salt thereof, and an antiandrogen, optionally in further combination with an additional anti-cancer agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.